

ScinoPharm ready with \$113 mn unit in China

13 December 2013 | News | By BioSpectrum Bureau



Singapore: Taiwan's leading maker of active pharmaceutical ingredients (APIs) has announced that the construction of its new \$113 million facility in China is now complete.

The company claimed in the official statement that the new facility is the first to be built in China to meet stricter requirements recently imposed by the China Food and Drug Administration. The new manufacturing and process development centre in Changshu, China the company explained, will make APIs for China and also for the international markets, US and Europe, in specific.

The statement added that the facility has been built on a 16 acre site in Changshu, in the Jiangsu province. The company also will be buying an adjoining 108 acres to expand the API manufacturing and to add formulation manufacturing facilities.

The statement specified that the new facility also includes an R&D operation and is able to manufacture high potency, anti-tumor, hormonal-active pharmaceutical ingredients and intermediates in highly contained facilities, as well as other APIs. It says it has developed 9 of the top 20 oncological products used in China and that regulators there have approved four of its APIs.

Singapore: Taiwan's leading maker of active pharmaceutical ingredients (APIs) has announced that the construction of its new \$113 million facility in China is now complete.

The company claimed in the official statement that the new facility is the first to be built in China to meet stricter requirements recently imposed by the China Food and Drug Administration. The new manufacturing and process development centre in Changshu, China the company explained, will make APIs for China and also for the international markets, US and Europe, in specific.

The statement added that the facility has been built on a 16 acre site in Changshu, in the Jiangsu province. The company also will be buying an adjoining 108 acres to expand the API manufacturing and to add formulation manufacturing facilities.

The statement specified that the new facility also includes an R&D operation and is able to manufacture high potency, anti-tumor, hormonal-active pharmaceutical ingredients and intermediates in highly contained facilities, as well as other APIs. It says it has developed 9 of the top 20 oncological products used in China and that regulators there have approved four of its

APIs.